Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORY-2001 in Mild to Moderate Alzheimer's Disease
NCT03867253Phase 2Completed
- Sponsor
- Oryzon Genomics
- Start
- May 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vafidemstat in Alzheimer's disease (AD), sponsored by Oryzon Genomics. Started May 2019; status: completed.
02
Drugs
vafidemstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03867253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867253.